France based Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to codevelop and co-commercialize an artificial intelligence (AI) solution to help clinicians diagnose and monitor patients with prostate cancer.

This agreement follows the first agreement signed in July 2018 between the two companies with the aim of using an artificial intelligence program to help clinicians diagnose and monitor patients with liver cancer.

Under this second program, Guerbet and IBM will work to develop a tool using artificial intelligence with the goal of helping to detect, segment, characterize and monitor lesions over time. This AI approach may allow for faster and more informed diagnosis of prostate cancer.

The AI solution for prostate will be designed for compatibility with most PACS (Picture Archiving and Communication System) visualization systems, which will make its direct integration into the workflows of healthcare professionals that much easier.